Expect a sharp negative stock reaction as the failure of a pivotal Phase 3 cardiovascular outcomes trial removes a major potential revenue driver. Monitor for analyst downgrades and potential pipeline revaluation. Ionis's other commercial medicines (TRYNGOLZA, DAWNZERA, ZANVASTRO) and pipeline may provide some offset, but the Lp(a) hypothesis setback is significant.
Price Chart
Executive Summary
Ionis Pharmaceuticals announced that its partner Novartis reported the Phase 3 Lp(a)HORIZON study of pelacarsen did not meet its primary endpoint of reducing cardiovascular events in patients with elevated Lp(a) and established cardiovascular disease. The trial enrolled 8,323 patients and achieved substantial Lp(a) lowering but failed to translate into cardiovascular risk reduction. This is a major clinical setback for Ionis's partnered pipeline asset.
Key Facts
- Phase 3 Lp(a)HORIZON study of pelacarsen did not meet its primary endpoint of reducing cardiovascular events (composite of CV death, non-fatal MI, non-fatal stroke, urgent coronary revascularization).
- Trial enrolled 8,323 patients with elevated Lp(a) and established cardiovascular disease.
- Pelacarsen substantially lowered Lp(a) levels but did not reduce cardiovascular risk.
- Pelacarsen demonstrated an acceptable safety profile.
- Ionis discovered and conducted early development; Novartis licensed rights in February 2019.
- Full data will be presented at an upcoming medical congress.
Financial Impact
No financial figures provided in the filing. The failure likely eliminates future milestone and royalty payments from Novartis for pelacarsen, a key pipeline asset.
Risk Factors
- Further pipeline setbacks or negative readouts from other programs.
- Dependence on Novartis for partnered programs may be reassessed.
- Potential for broader negative sentiment on Lp(a) targeting therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-035802 |
| Document: ef20081690_ex99-1.htm | 0001140361-26-035802 |
| Document: 0001140361-26-035802-index-headers.html | 0001140361-26-035802 |
| Document: 0001140361-26-035802-index.html | 0001140361-26-035802 |
| Document: 0001140361-26-035802.txt | 0001140361-26-035802 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | 8-K | $56.71 $47.25 | ▲ +16.68% | ▲ +15.56% | $43.50 (+23.29%) |
Sep 4, 2026 28d ago | 8-K | $58.09 $51.44 | ▼ −11.45% | ▼ −10.24% | $43.50 (−25.12%) |
Jul 31, 2026 9w ago | Insider Buy | $51.77 $56.56 | ▲ +9.25% | ▲ +5.74% | $43.50 (−15.97%) |
Jul 29, 2026 9w ago | 8-K | $54.04 $54.19 | ▲ +0.28% | ▼ −5.25% | $43.50 (−19.50%) |
Jul 10, 2026 12w ago | 8-K | $58.25 $54.65 | ▼ −6.18% | ▼ −5.62% | $43.50 (−25.32%) |
Jul 9, 2026 12w ago | Insider Cluster | $58.25 $54.65 | ▼ −6.18% | ▼ −5.62% | $43.50 (−25.32%) |
Jul 9, 2026 12w ago | Insider Cluster | $58.25 $54.65 | ▼ −6.18% | ▼ −5.62% | $43.50 (−25.32%) |
Jul 9, 2026 12w ago | 8-K | $64.27 $54.65 | ▲ +14.97% | ▲ +14.84% | $43.50 (+32.32%) |
Jun 30, 2026 13w ago | Insider Cluster | $79.19 $86.33 | ▲ +9.02% | ▲ +8.75% | $43.50 (−45.07%) |
Jun 30, 2026 13w ago | Insider Cluster | $79.19 $86.33 | ▲ +9.02% | ▲ +8.75% | $43.50 (−45.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access